Fairvalue-Calculator Fairvalue-Calculator
EN DE

Intech Biopharm Corporation (6461) Fair Value & Analysis

Healthcare · TW · Market cap 2.8B TWD

Price15.20 TWD
Fair Value27.78 TWD
Upside+82.8%
Quality95/100
Evidence: Low Range 20.83 TWD – 34.72 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Intech Biopharm Corporation (6461) currently trades at 15.20 TWD, while our model-based Fair Value estimate is 27.78 TWD — implying the stock looks roughly 82.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Intech Biopharm Corporation (6461) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 27.78 TWD versus a price of 15.20 TWD — about +83% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6461?
Our 21-model fair value for Intech Biopharm Corporation is 27.78 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 15.20 TWD.
What is the quality score of 6461?
Intech Biopharm Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.